Table 3.

Univariate and multivariate analyses of association between clinical characteristics and developing for medication-related osteonecrosis of the jaw in patients who received denosumab or zoledronic acid for bone metastases

Variables	Univariate analyses			Multivariate analysis
	Hazard ratio	95% CI	P value	Hazard ratio	95% CI	P value
Denosumab treatment	4.28	1.81–11.86	0.001	6.53	2.62–19.12	< 0.001
Age (> 65 years)	2.43	1.10–6.15	0.028	3.34	1.46–8.68	0.004
Tooth extraction before starting BMAs	3.06	1.50–6.33	0.002	3.52	1.70–7.44	0.001
Tooth extraction after starting BMAs	3.82	1.61–8.39	0.004	3.74	1.51–8.42	0.006
Male sex	1.03	0.50–2.17	0.936	N/A
Weight (kg)	0.99	0.96–1.03	0.743	N/A
Hypertension	1.27	0.61–2.63	0.513	N/A
Diabetes	0.49	0.12–1.40	0.201	N/A
Concomitant use of antiangiogenic agents a	1.35	0.59–2.89	0.460	N/A
Concomitant use of steroids	1.37	0.66–2.98	0.405	N/A

CI confidence interval, BMA bone-modifying agent

N/A indicates that the covariate was not included in the model because it was not significant in univariate analyses

^aIncludes axitinib, bevacizumab, everolimus, pazopanib, ramucirumab, regorafenib, sorafenib, sunitinib, and temsirolimus